considered for safety. There are species-specific differences in metabolic pathway capacity that must be considered, as pig skin is increasingly being recommended by regulatory agencies and industry worldwide for in vitro skin absorption studies. Specific metabolic pathways in skin, such as cytochrome P450, have relatively low activity when compared with the liver. Pig skin metabolism may not always equate to human skin metabolism. Pig skin (29), human-derived EpiSkin S9 (33) fractions, and other in vitro human skin models have utility for initial chemical screening in a qualitative manner. However, if metabolism is deemed important as it relates to skin absorption, there may not be a completely acceptable skin model substitute for viable intact human skin use in a human safety assessment (29).

REFERENCES

1. Oesch F, Fabian E, Landsiedel R. Xenobiotica-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models. Arch Tox 2018; 92:2411–2456.
2. Smith LH, Holland JM. Interaction between benzo[a]pyrene and mouse skin in organ culture. Toxicology 1981; 21:47–57.
3. Holland JM, Kao JY, Whitaker MJ. A multisample apparatus for kinetic evaluation of skin penetration *in vitro*: the influence of viability and metabolic status of skin. Toxicol Appl Pharmacol 1984; 72:272–280.
4. Yengi LG, Xiang Q, Pan J, Scatina J, Kao J, Ball SE, Fruncillo R, Ferron G, Wolf CR. Quantitation of cytochrome P450 mRNA levels in human skin. Analytical Biochemistry 2003; 316:103–110.
5. van Eijl S, Zhu Z, Cupitt J, Gierula M, Götz C, Fritsche E, Edwards RJ. Elucidation of xenobiotic metabolism pathways in human skin and human skin models by proteomic profiling. PLoS ONE 2012; 7(7):e41721.
6. Luu-The V, Duche D, Ferraris C, Meunier JR, Leclaire J, Labrie F. Expression profiles of phases 1 and 2 metabolizing enzymes in human skin and the reconstructed skin models Episkin™ and full thickness model from Episkin™. J Steroid Biochem Mol Biol 2009; 116:178–186.
7. Hu T, Khambatta ZS, Hayden PJ, Bolmarcich J, Binder RL, Robinson MK, Carr GJ, Tiesman JP, Jarrold BB, Osborne R, Reichling TD, Nemeth ST, Aardema MJ. Xenobiotic metabolism gene expression in the EpiDerm™ *in vitro* 3D human epidermis model compared to human skin. Toxicol in Vitro 2010; 24: 1450–1463.
8. OECD. Test No. 428: Skin Absorption: In Vitro Method. OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, 2004.
9. Hawkins GS, Reifenrath WG. Influence of skin source, penetration cell fluid, and partition coefficient on *in vitro* skin penetration. J Pharm Sci 1986; 75:378–381.
10. Collier SW, Sheikh NM, Sakr A, Lichtin JL, Stewart RF, Bronaugh RL. Maintenance of skin viability during *in vitro* percutaneous absorption/metabolism studies. Toxicol Appl Pharmacol 1989; 99:522–533.
11. Hood HL, Bronaugh RL. A comparison of skin viability assays for *in vitro* skin absorption and metabolism studies. In Vitro Mol Toxicol 1999; 12:3–9.
12. Oesch F, Fabian E, Oesch-Bartlomowicz B, Werner C, Landsiedel R. Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab Rev 2007; 39:659–698.
13. Pyo SM, Maibach HI. Skin metabolism: relevance of skin enzymes for rational drug design. Skin Pharmacol Physiol 2019; 32:283–293.
14. Kazem S, Linssen EC, Gibbs S. Skin metabolism phase I and phase II enzymes in native and reconstructed human skin: a short review. Drug Discov Today 2019; 24(9):1899–1910.
15. Chellquist EM, Reifenrath WG. Distribution and fate of diethyl malonate and diisopropyl fluorophosphate on pig skin *in vitro*. J Pharm Sci 1988; 77:850–854.
16. Wiegand C, Hewitt NJ, Merk HF, Reisinger K. Dermal xenobiotic metabolism: a comparison between native human skin, four *in vitro* skin test systems and a liver system. Skin Pharmacol Physiol 2014; 27:263–275.
17. Bronaugh RL, Stewart RF, Storm JE. Extent of cutaneous metabolism during percutaneous absorption of xenobiotics. Toxicol Appl Pharmacol 1989; 99:534–543.
18. Storm JE, Collier SW, Stewart RF, Bronaugh RL. Metabolism of xenobiotics during percutaneous penetration: role of absorption rate and cutaneous enzyme activity. Fund Appl Toxicol 15:132–141, 1990.
19. Collier SW, Storm JE, Bronaugh RL. Reduction of azo dyes during *in vitro* percutaneous absorption. Toxicol Appl Pharmacol 1993; 118:73–79.